Grants

National Institutes of Health

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes.

Up to $499K

2028-01-07

EducationHealth

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerated aging in the CNS of SIV-infected macaques

NIA - National Institute on Aging

PROJECT SUMMARY ABSTRACT HIV infection results in numerous complications across multiple organ systems, with over 75% of patients with chronic HIV disease showing clinical manifestations, even when on long-term successful combination antiretro- viral therapy (ART). Additional inflammatory sequelae have patients on long-term successful ART therapy who suffer from residual and end organ diseases of HIV infection. We posit that astrocyte dysfunction in key brain regions is central to HIV-associated accelerated aging. Activated astrocytes are associated with increased leu- kocyte transmigration, HIV infection, and the establishment of a highly inflammatory environment, which further aggravates HIV-associated disease, including accelerated aging and associated cognitive decline. Thus, as glia are present in all brain regions, and can be exposed to virus and viral proteins during acute infection, glia will be activated before treatment can be administered. Chronic activation of glia are known to impact the blood-brain barrier and can be an underlying cause of fronto-temporal and vascular dementias. Numerous studies are show- ing that the chronic activation of glia following SIV infection leads to an accelerated aging phenotype, including cognitive decline. Long-term ART may diminish the neurodegeneration observed in chronic SIV infection but have minimal impact on accelerated aging in glial cells observed in multiple brain regions. Due to the protean nature of early HIV infection, it is likely that, even under the best of care, ART is administered only after several weeks of infection. However, ART is administered early after exposure in the case of post- exposure prophylaxis (PEP). To date, there are very few studies examining glial activation during PEP. Before attempting a targeted treatment strategy, it will be necessary to tease out the underlying pathways of activation and determine if it is even possible to prevent the aging from happening in the first place. To this end, we are proposing a group of animals that will begin treatment at the very earliest stage of infection. Dysregulation of glial function and associated accelerated aging, especially in the context of successful ART suppression of SIV infection, represents a significant gap in our knowledge. Therefore, there is a critical need to understand the mechanisms of SIV-induced inflammaging and the influence of very early versus ART administration after viral setpoint, including downstream cognitive function. This multidisciplinary R01 application, which piggy-backs on several NIH-funded projects, seeks to address how long-term successful ART influences the activation of astro- cytes, focusing on mechanisms of inflammaging and neurodegeneration in multiple brain regions.

Up to $872K

2031-05-31

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerated Antibody Evolution Under Functional Selection

NCATS - National Center for Advancing Translational Sciences

PROJECT SUMMARY Antibodies have proven to be a powerful and effective therapeutic strategy, with successful drugs targeting a variety of pathways. New antibodies can be developed by animal inoculation or by ex-vivo methods such as phage-display. The former harnesses the power of somatic hypermutation that is a natural component of the mammalian immune system, while the latter circumvents the labor and cost associated with animal experimentation. Both approaches produce antibodies characterized by strong binding to the antigen target of interest. Strongly binding antibodies must then be further screened to determine their functional activity, namely their ability to either stimulate or block activity in a specific cell signaling receptor. Importantly, these approaches do not harness the power of evolution to optimize the functional characteristics of the antibody. The goal of this project is to develop an in vitro method to perform rapid antibody evolution, where selection is performed based on the function of the antibody rather than just the strength of antigen binding. Specifically, the project will aim to develop allosteric modulators for G protein-coupled receptors (GPCR), which are the largest family of membrane proteins in humans and broadly represented across nearly all physiological and pathophysiological processes. The project will leverage an engineered system in which a yeast plasmid replicates orthogonally from the rest of the yeast genome such that the plasmid is copied with a high error rate to produce rapid evolution while the rest of the yeast genome is replicated with low error rate to maintain the health of the organism. Antibody fragment sequences will be encoded on the rapidly mutating plasmid and secreted by the yeast. The yeast will be encapsulated in microfluidic double-emulsion droplets together with mammalian GPCR reporter cells. Antibody function will thus be quantified by fluorescent reporter, and droplets containing yeast with a desired functionality can be selected via droplet sorting by conventional fluorescence-activated cell sorting. After droplet demulsification, the selected yeast can be further expanded to continue the evolutionary process.

Up to $414K

2028-05-31

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerated Biological Aging and Immunosenescence as Drivers for Racial Disparities in Monoclonal Gammopathy of Undetermined Significance (MGUS)

NCI - National Cancer Institute

PROJECT SUMMARY Multiple myeloma (MM) is an incurable plasma cell malignancy and the most common blood cancer among individuals who self-identify as African American, accounting for ~20% of newly diagnosed cases. The biological factors contributing to the increased risk of MM and its precursor condition, monoclonal gammopathy of undetermined significance (MGUS), in individuals of African ancestry remain poorly understood. Strikingly, when access to healthcare is equal, African American patients experience better clinical outcomes, and their MM tumors exhibit lower genomic complexity compared to those of European American patients. It is well established that the incidence of MGUS and MM increases with age, and aging is a primary determinant for progression from MGUS to MM. African American patients are diagnosed with MGUS and MM at younger average ages than European American patients, and emerging evidence suggests that individuals of African ancestry exhibit accelerated biological aging and immunosenescence. Together, these observations suggest that accelerated biological aging may contribute to the higher prevalence of MGUS and increased incidence of MM in African Americans. In support of this, we found that African American patients with MGUS and MM, as well as healthy donors, had increased CD57+ CD8+ T cells, a hallmark of immunosenescence. This altered immune function may reduce tumor immune surveillance, decreasing the selective pressure that drives tumor immunoediting. We hypothesize that individuals with predominant African ancestry who develop MGUS or MM experience accelerated biological aging and immunosenescence compared to those with predominant European ancestry, resulting in reduced tumor immunoediting and the development of tumors with less genomic complexity- a feature linked to more favorable clinical outcomes. In Aim 1, we will assess whether patients with MGUS and MM who have predominant African ancestry exhibit accelerated biological aging compared to those with predominant European ancestry. In Aim 2, we will compare the immune tumor microenvironment in MGUS and MM patients with predominant African ancestry vs. those with predominant European ancestry to test the hypothesis that African ancestry patients exhibit increased immunosenescence. In Aim 3, we will evaluate whether MM tumors from patients with predominant African ancestry exhibit reduced immunoediting relative to those from patients with European ancestry. To mechanistically model this, we will use a mouse MM tumorigenesis model and apply unpredictable chronic mild stress to mimic chronic environmental and psychosocial stressors to test whether tumors arising under stress exhibit reduced immuno editing, evidenced by decreased genomic complexity and the reduced ability to engraft in immunocompetent recipient mice. Overall, this work will elucidate the role of accelerated biological aging and immunosenescence as potential drivers for increased MM incidence in individuals with African ancestry.

Up to $558K

2031-04-30

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerated Epithelial Cell Detachment in Progression of Kidney Disease

NIH

Chronic kidney disease (CKD) is a progressive condition that puts a substantial burden on individuals, families, and health care systems. CKD is already a leading cause of death world-wide, and the incidence and prevalence is expected to rise. CKD is about 34% more common in veterans than in the general population, and U.S. Department of Veterans Affairs cares for over 600,000 veterans with CKD. The VA spents approximately $18 billion for the care of patients with CKD without including costs for kidney replacement therapy (KRT). Research has established a multi-modular therapeutic approach that delays progression of CKD, but the residual risk remains unacceptably high. TGF beta (TGFβ) pathway is a key-mechanisms for progression of kidney disease, which has multiple cell-type specific divergent effects. Therefore, focusing on more specific downstream mediators within the pathway is a promising strategy for intervention. We identified TGF-beta1 (TGFβ1) signaling as the central upstream mediator of podocyte loss, a mechanism for progression of kidney disease, in kidney tissue of patients with early-stage kidney disease. Further analysis identified TGFβ-induced (TGFBI), a TGFβ1 downstream target gene and secreted protein that functions as anti-adhesive factor, as one of the top genes associated with podocyte depletion. Furthermore, we found that TGFBI is strongly up regulated in kidney biopsy tissue from patients with FSGS and diabetic kidney disease (DKD) and in Tgfβ-transgenic mice (Tgfβ-TG), a model of progressive glomerulosclerosis, in which podocyte loss is a prominent phenotype and mechanisms of disease progression. In cultured human podocytes, exogenous TGFBI treatment led to disruption of the cytoskeleton and podocyte detachment. Furthermore, we determined that increased urinary amounts of TGFBI were highly significant associated with progression in patients with kidney disease, in particular DKD. We hypothesize that TGFBI promotes podocyte loss by decreasing attachment of podocytes to GBM, thereby leading to glomerulosclerosis and progressive renal failure. We specifically aim to determine whether TGFBI mediates podocyte loss in mice that are either deficient for or overexpress Tgfbi and have diabetic kidney disease induced by streptozotin plus uni-nephrectomy mice (Aim 1). Furthermore, we propose to determine the molecular mechanisms underlying TGFBI-mediated podocyte loss by assessing podocyte attachment, cytoskeleton rearrangement, activation of cell-death signaling, binding of TGFBI to integrins and other ECM and cell membrane proteins in cultured human podocytes (Aim 2). In addition, we will assess whether urinary TGFBI (uTGFBI) is associated with intra-renal TGFβ/Smad signaling activity, renal pathologic changes and adverse clinical outcomes in patients with kidney disease in patients enrolled in observation clinical cohort of Clinical Phenotyping and Resource Biobank Core (C-PROBE) (Aim 3). If successful, these studies will justify future research developing interventions that target the TGFBI- induced podocyte detachment and potentially other detrimental effects on renal epithelial cells.

2030-03-31

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerating discovery of narrow-spectrum antibiotics for Lyme disease

NIAID - National Institute of Allergy and Infectious Diseases

PROJECT SUMMARY The development of narrow-spectrum antibiotics against the Lyme disease-causing bacterium, Borrelia burgdorferi has the potential to significantly alter current approaches to the treatment and prevention of Lyme disease. Narrow-spectrum agents that affect only the target bacteria avoid issues of propagation of resistance in off-target bacteria, alterations in microbiome, and overgrowth of pathogenic bacteria. However, physical screening of compounds for activity against multiple bacteria such as through traditional high-throughput screens is highly inefficient due to its very low “hit” rate for activity against B. burgdorferi (<0.3%). Even when “hits” are found downstream testing for toxicity, studies of pharmacokinetics, and mechanisms of action are time- consuming and costly. Advances in machine learning can accelerate narrow-spectrum antibiotic development by more efficiently and comprehensively searching the vast potential space of small molecule candidates to identify the optimal balance of inhibitory properties, bio-availability, and toxicity. In this project, we propose to develop two modeling-based platforms to accelerate drug development efforts for Lyme disease using combinations of computational and experimental approaches. The first platform will use machine learning to design compounds with predicted activity against B. burgdorferi but not other bacteria using high throughput screening data from B. burgdorferi, E. coli and S. aureus. This framework will be biologically and chemically informed in an automated way using medical literature agents, predicted proteome binding, and machine learning models of bioavailability and toxicity. The second platform will focus on speeding identification of mechanisms of action of novel agents using a multi-omic profiling model across dimensions of morphology and transcriptional response to known agents to generate predictive models. In the process of developing these tools, our work will also produce drug response profiles for a diverse range of antibiotics against B. burgdorferi for the first time. We anticipate that when this project is completed, we will have developed new computational and experimental technologies that can dramatically accelerate the drug development pipeline for Lyme disease and from which drug development pipelines for other hard to treat pathogens may be created.

Up to $859K

2031-01-31

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01 Clinical Trial Not Allowed)

National Institutes of Health

The purpose of this Program Announcement with Special Receipt, Referral, and/or Review Considerations (PAR) is to solicit applications to access stored blood plasma, blood serum, and extracted DNA from the All of Us Research Program supported Biobank to advance the program's mission of accelerating health research and medical breakthroughs, enabling individualized prevention, treatment, and care for all of us.All of Us partnered research studies are collaborative initiatives funded by a study sponsor external to All of Us to collect and add new data to the All of Us Researcher Workbench in accordance with All of Us" best practices. All of Us partnered research studies are open to the broad scientific community and require investigators to apply for and receive an X01 award under this announcement.This will enable longitudinal follow‐up and repeat sampling, and provide multiomic data (genomics, proteomics, metabolomics, and other high‐dimensional molecular profiles), integrated clinical, environmental, and life‐course data, infrastructure designed to support future clinical‐trial recruitment, and public‐private partnership pathways.This opportunity will enable researchers to conduct assays to evaluate associations between newly collected and existing All of Us data and add new data to the All of Us dataset for broad use by the research community. High-priority areas for biospecimen analyses may include, but are not limited to, large scale projects that propose integrated multiomics analyses, early disease detection, biomarker discovery or validation, novel risk models for incident disease, and/or novel disease stratification for chronic disease risk, diagnosis, and prognosis, in support of advancing precision medicine. For more information, please visit the All of Us X01 Partnered Research Studies Resource webpage.

2027-03-01

Health

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01 Clinical Trial Not Allowed)

National Institutes of Health

The purpose of this Program Announcement with Special Receipt, Referral, and/or Review Considerations (PAR) is to solicit applications to access stored blood plasma, blood serum, and extracted DNA from the All of Us Research Program supported Biobank to advance the program's mission of accelerating health research and medical breakthroughs, enabling individualized prevention, treatment, and care for all of us.All of Us partnered research studies are collaborative initiatives funded by a study sponsor external to All of Us to collect and add new data to the All of Us Researcher Workbench in accordance with All of Us" best practices. All of Us partnered research studies are open to the broad scientific community and require investigators to apply for and receive an X01 award under this announcement.This will enable longitudinal follow up and repeat sampling, and provide multiomic data (genomics, proteomics, metabolomics, and other high dimensional molecular profiles), integrated clinical, environmental, and life course data, infrastructure designed to support future clinical trial recruitment, and public private partnership pathways.This opportunity will enable researchers to conduct assays to evaluate associations between newly collected and existing All of Us data and add new data to the All of Us dataset for broad use by the research community. High-priority areas for biospecimen analyses may include, but are not limited to, large scale projects that propose integrated multiomics analyses, early disease detection, biomarker discovery or validation, novel risk models for incident disease, and/or novel disease stratification for chronic disease risk, diagnosis, and prognosis, in support of advancing precision medicine. For more information, please visit the All of Us X01 Partnered Research Studies Resource webpage.

2027-03-01

Healthhealthcare

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerating FAIR4RS Clinical Patient Accrual through Standardized Infrastructure for In-Silico Clinical Phenotyping

NLM - National Library of Medicine

PROJECT ABSTRACT/SUMMARY The main objective of this proposal is to obtain support for Andrew Wen, MS, a research software engineer and data scientist at the University of Texas Health Science Center at Houston. Mr. Wen supports the development and dissemination of research tooling and infrastructure at the Center for Translational AI Excellence and Applications in Medicine (TEAM-AI) under the direction of Hongfang Liu, PhD. Mr. Wen's career has a demonstrated focus in the design, implementation, and dissemination of open-source research infrastructure, particularly with a focus on management, analysis on, and information retrieval from large repositories of unstructured clinical research data. This award would allow for 3 years of funding for Mr. Wen to lead development and dissemination of research tooling to facilitate accrual and management of patient cohorts via in-silico clinical phenotyping, with an initial use case on rare disease cohort identification. The benefits of development and dissemination of this tooling are two-fold: 1) by distributing tooling suited for the purpose, we accelerate data cohort accrual, which is often a bottlenecking step in clinical artificial intelligence research, particularly with respect to query generation/development from natural language and human-in-the-loop evidence review and relevance judgement, and 2) improving research reproducibility and compliance with FAIR4RS principles by ensuring that appropriate metadata for dataset curation is routinely stored and retained as part of standard, sharable, tooling.

Up to $160K

2029-07-31

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerating Platforms for Evaluating and eXecuting AI Lifecycles in ADRD (APEX-ADRD)

NIA - National Institute on Aging

PROJECT SUMMARY/ABSTRACT | OVERALL STRATEGY Despite the 7M Americans living with Alzheimer’s disease and related dementias (ADRD) at an annual cost exceeding $781B, and nearly half of dementia cases being potentially preventable, artificial intelligence (AI) has yet to deliver its promised transformation in aging and ADRD care. Few AI-based clinical decision support tools for ADRD exist and were typically cleared through low-evidence pathways. Markedly, current validation pro- cesses often require years, which is too slow for AI, a technology that is quickly evolving. As a result, clinicians and patients are without trustworthy guidance on which tools help or harm. The gap is growing between innova- tion and evidence, particularly for vulnerable older adults with ADRD. Objectives and impact. The UCLA Accelerating Platforms for Evaluating and Executing AI Lifecycles in ADRD (APEX-ADRD) Collaboratory will transform how AI is developed, tested and deployed for aging and ADRD pop- ulations. Our goal is to stimulate transformative research across the NIA Stage Model (Stages 0-V) and compress timelines from years to months while preserving rigor, safety, and fairness. APEX-ADRD will serve as a national resource to accelerate responsible AI by: 1) building governance and infrastructure for rapid, reproducible eval- uation; 2) catalyzing innovation via design studios that embed co-design and ethics early in the process, along with access to unique data resources; and 3) establishing best practices for ethical and fair AI including contin- uous post-deployment fairness monitoring. UCLA brings unmatched multidisciplinary capacity to lead this effort with demonstrated track records in both the development of novel AI methods deployed into real- world healthcare settings as well as dynamic and comprehensive evaluation strategies. Notably, through our Collaboratory, pilot projects will have access to the University of California (UC) Health Data Warehouse (8.7M patients; 152K ADRD) for in silico validation with electronic health record (EHR) data and imaging; the ATLAS biobank (150K UCLA genotyped patients with EHR data); and other national datasets. This infrastructure is coupled with active guidance from leaders in geriatrics, neurology, biomedical informatics, computer sci- ence/AI, biostatistics, bioethics, health economics, implementation science, and the human-AI interface. Im- portantly, APEX-ADRD brings a strong industry and stakeholder team and will work closely with the AITC Coor- dinating Center and the trans-AITC Stakeholder Engagement Team to ensure all pilots integrate end-user feed- back, algorithmic fairness metrics, and common evaluation tools. Collectively, these facets are integrated throughout the Collaboratory’s services to ensure the success of AI pilot projects in aging and ADRD. By creating scalable models for safe and fair AI evaluation, UCLA’s APEX-ADRD will accelerate national progress toward improving health, independence, and quality of life for older adults and persons living with ADRD.

Up to $4.9M

2031-06-30

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerating Research and Development of Next Generation Malaria Vaccines Against Malaria – A Model for Mosquito-Borne Diseases

upcoming

National Institutes of Health

<p>The National Institute of Allergy and Infectious Diseases (NIAID) seeks to support basic research, discovery, and/or preclinical development of highly efficacious vaccines for malaria and potentially other mosquito-borne illness. The program will encourage novel approaches to vaccine design that capitalize on recent technological innovations including structure-based immunogen design, and/or combination vaccines to reduce parasite infection and/or reduce malaria disease burden. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.</p>

2027-02-11

Health

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerating Research and Development of Next Generation Malaria Vaccines Against Malaria – A Model for Mosquito-Borne Diseases

upcoming

National Institutes of Health

Accelerating Research and Development of Next Generation Malaria Vaccines Against Malaria – A Model for Mosquito-Borne Diseases

Rolling

research

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerating Research and Development of Next Generation Malaria Vaccines Against Malaria A Model for Mosquito-Borne Diseases

upcoming

National Institutes of Health

The National Institute of Allergy and Infectious Diseases (NIAID) seeks to support basic research, discovery, and/or preclinical development of highly efficacious vaccines for malaria and potentially other mosquito-borne illness. The program will encourage novel approaches to vaccine design that capitalize on recent technological innovations including structure-based immunogen design, and/or combination vaccines to reduce parasite infection and/or reduce malaria disease burden. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.

2027-02-11

Healthhealthcare

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerating Research through International Network-to-Network Collaborations

U.S. National Science Foundation

The contemporary research landscape is a collaborative and international enterprise requiring high level coordination among multi-disciplinary, cross-cultural teams. As such, the Accelerating Research through International Network-to-Network Collaborations program (AccelNet) values cooperation over competition. Program goals are to 1) leverage prior NSF support for building research capacity towards activities that launch international research network of networks (NoN) that will lead to an accelerated advancement of an area of science after the award period and 2) recruit and foster a diverse and internationally competent US-based workforce trained in conducting and leading multi-team international collaboration. Any area funded by the National Science Foundation is eligible, particularly those addressing grand research challenges identified within research communities and/or by NSF. Successful proposals will demonstrate that the proposed activities will: 1) accelerate scientific research at a rate that would not be possible without concerted international cooperation in research planning; 2) make NoN members more competitive for research awards following the period of award; 3) recruit and foster a US-based diverse and internationally competent workforce trained in conducting and leading multi-team international collaboration. Proposals must include detailed plans for collaborative networking activities that will result in a synergy of effort across the entire NoN. The AccelNet Program has two tracks. The Design Track allows PIs to build on prior research by providing time and resources for building capacity across teams to launch a synergistic international NoN. The Implementation Track allows PIs to build on prior research or networking activities by providing time and resources to implement an international NoN. There are two phases to the Implementation Track. Phase 1 funding is for activities related exclusively to NoN activities and is open to all PIs, including but not limited to prior successful Design Track PIs. Phase 2 funding is for early concept research arising from Phase 1 activities and is only open to Phase 1 PIs who have identified a critical research gap during synergistic networking activities in the first 18-24 months of Phase 1 awards.

rolling

sciencetechnology

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerating Solutions to Improve Access and Quality of Empirically-Supported Practices for Youth Mental Health (R01 Clinical Trial Optional)

National Institutes of Health

This NOFO is a call to action in response to the mental health crisis in the United States. We seek applications that will study methods to increase access to evidence-based interventions and services for youth mental health, including those living in rural areas, inner cities, and other under-resourced areas, and youth experiencing housing and food insecurities and out-right homelessness. Applications should address research related to optimizing assessment, intervention and service strategies, overcoming challenges related to the workforce shortage, wait lists for treatment, integration of treatment and preventive interventions into settings where people are most likely to be best identified as needing care (eg: schools, social service, pediatric medicine and justice), and service interventions that address systemic barriers to access and quality of mental health care (structural, policy, organizational, value (cost/financing), management).

2027-01-07

HealthHousing

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerating Solutions to Improve Access and Quality of Empirically-Supported Practices for Youth Mental Health (R01 Clinical Trial Optional)

National Institutes of Health

2027-01-07

Healthhealthcare

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerating Speed to Power/Winning the Artificial Intelligence Race: Federal Action To Rapidly Expand Grid Capacity and Enable Electricity Demand Growth

infrastructurestem_integration

Energy Department

Projected electricity demand growth from data centers, advanced manufacturing facilities, semiconductor fabrication plants, and other large energy users is outpacing the capacity of the existing electric grid. The Department of Energy (DOE) is inviting public input and seeking detailed information via this request for information (RFI) from state energy offices, public utility commissions, electric utilities, regional transmission organizations and independent system operators, transmission and generation developers, large energy users, and other stakeholders on large-scale generation, transmission, and grid infrastructure projects that can accelerate speed to power to support manufacturing, industrial, and artificial intelligence/data center electricity demand growth. In addition, DOE is requesting stakeholder input on how to best utilize its funding programs and authorities to rapidly expand energy generation and transmission grid capacity to meet electricity demand growth across the country in a reliable and affordable manner.

See notice

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerating the Incorporation of Climate Change Knowledge into Adaptation Planning for National Park Service Assets in the Great Lakes Region

National Park Service

The project will extend the information developed for the 2013 ISRO project to Apostle Islands NL (APIS), which shares climate and weather vulnerabilities with ISRO. The University of Michigan will reuse the resources and processes completed during the ISRO project to engage park staff and provide climate information that balances management expectations, usability, and resources with scientific salience, credibility and legitimacy. The goal is to streamline the process of developing the necessary climate science, at a management-relevant scale, to allow NPS professionals to re-use basic climate scenarios toward a variety of management issues. The cooperators will use the GLISAclimate.org database to determine overlap of climate drivers between ISRO and APIS with the goal to enable and support the provision of tailored climate information and the generation of climate scenarios to meet NPS goals. The ISRO scenario work focused on specific management decisions around changing vegetation patterns and impacts to large mammals. Following the identification of APIS management needs,, cooperators will pursue a set of applications that will inform decisions related to these needs. The work will be transferable and will result in a resource foundation that can be extended to national parks and other public and private entities in the Upper Great Lakes Region.

$1 – $46K

rolling

natural resources

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)

National Institutes of Health

The purpose of this Notice of Opportunity Announcement (NOFO) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders, prevention of drug use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of drug using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of drug abuse and HIV.

HealthEducation

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)

National Institutes of Health

Education

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)

National Institutes of Health

The purpose of this notice of funding opportunity (NOFO) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders, prevention of drug use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of drug using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of drug abuse and HIV.

EducationHealth

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)

National Institutes of Health

Education

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerating Time-to-Treatment in Rural Areas with a Pre-Hospital EEG Stroke Classification System

NIMHD - National Institute on Minority Health and Health Disparities

Stroke is the second leading cause of death and the primary cause of long-term disability worldwide costing the US $65B every year. A study of nearly 7,000 stroke patients revealed that the average onset-to-intervention time was nearly 4hrs, with the best outcomes achieved under three hours and statistically significant improvements for each 15-minute window under that threshold. Timely interventions can reduce long-term disability, but not all interventions work for different types of stroke. 87% of strokes are ischemic in nature (AIS), but administering anti-coagulants to the 13% of hemorrhagic stroke patients would be disastrous. Because current EMS capabilities cannot reliably differentiate between ischemic and hemorrhagic stroke before hospital arrival, very few are treated with tPA within the critical first hour. Disparities further widen in rural areas, where stroke patients are 50% less likely to receive intravenous thrombolysis and have 8% higher mortality than urban patients. Only 26% of rural residents live within a 30-minute drive of a certified stroke center (versus 70% of urban residents) making intervention during the “golden hour” highly unlikely. To address this gap, this project will use a CE marked and FDA-cleared EEG system to record and analyze EEG signals to provide a real-time stroke classification solution that works within or alongside mobile stroke units (MSUs) and standard EMS. This is paired with a machine learning model that autonomously eliminates artifacts and accurately triages suspected stroke patients for the fast identification of ischemic/hemorrhagic stroke in the pre-hospital setting. Our product was initially created to detect large vessel occlusion for optimal routing of patients to comprehensive stroke centers for endovascular therapy. Stroke vs non-stroke models operate at an AUC >0.95 and LVO vs non-LVO an AUC of 0.90. Additional work is being conducted with the Los Angeles County Emergency Medical Services Agency. This Phase I project pursues three specific aims. 1) Multi-site clinical validation of EEG-based detection of hemorrhagic stroke. Data will be collected from EMS environments to ensure model performance in real-world settings. The target is an AUC ≥0.90 for ischemic vs. hemorrhagic classification. Secondary goals include sensitivity and specificity ≥85% with special emphasis on achieving high hemorrhagic sensitivity to support safe tPA decisions in prehospital care. 2) Ensure EEG signal robustness across diverse hair types. Previous studies have shown that certain phenotypes pose challenges for electrode recordings. The goal is to demonstrate non disparity between hair type subgroups with <5% performance decrement between any two groups. 3) Integrate the system into EMS workflows and optimize the user interface for real-time decision support. The goal is to achieve setup times of less than five minutes and user satisfaction ratings exceeding 85%. By the conclusion of Phase I, it is expected to demonstrate that the system can classify ischemic vs. hemorrhagic stroke in under five minutes, setting the stage for impact assessment in Phase II.

Up to $314K

2027-07-31

Free to search & build · $99 one-time to unlock the application pack · No subscription

Accelerating Translational Research to Integrate Maternal, Fetal and Infant Health

NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development

SUMMARY Relevant to NICHD’s mission is prioritizing research to improve the health of American children and families. Similarly, reducing the prevalence of childhood chronic diseases by understanding and diminishing contributions to disease risk is a goal of the Make American Healthy Again initiative. The proposed conference is unique in that it focuses specifically on the relatively new field of prenatal pediatrics; that is, optimizing fetal well-being through maternal-fetal research and fetal interventions to improve outcomes in the neonatal period and beyond. Our MPI team at the Prenatal Pediatrics Institute (Adre duPlessis, MBChB) and the Developing Brain Institute (Catherine Limperopoulos, PhD, and Katherine L. Wisner, MD, MS) at Children’s National Hospital (CNH) has evolved a progressive model of in utero pediatric care to underscore the importance of pregnancy and the womb as the time and place where childhood chronic disease first takes hold. The fetal environmental milieu has a key role in defining the trajectory of life-long health. Our objective is to concentrate on the potential of prenatal pediatrics as a powerful conceptual framework to guide research to reduce the escalating rates of childhood chronic diseases. Examining the potential dietary, behavioral, medical, and socio- environmental factors associated with childhood chronic disease is crucial to encourage interdisciplinary, evidence-based research to inform interventions, societal change, and policy. This conference was developed with the goal of reducing institutional and research compartmentalization. We plan two days of presentations by speakers representing a broad array of prenatal pediatrics/neonatology and subspecialties, maternal-fetal medicine, perinatal mental health, translational scientists in non-invasive technologies to evaluate fetal health, genetics/epigenetics, nutrition, infectious disease and the microbiome, public health, artificial intelligence and data science. Conference meals include extended periods of time for lunch and a dinner to support delegate networking. A final panel including the MPIs and Dr. Yoel Sadovsky will synthesize the conference proceedings and generate recommendations to advance the field. Manuscripts will be developed from the lectures for publication in an issue of the journal Seminars in Perinatology focusing on the theme, Translational Research to Integrate Maternal, Fetal and Infant Health.

Up to $10K

2027-05-31